APA

Curigliano G., Romieu G., Campone M., Dorval T., Duck L., Canon J., Roemer-Becuwe C., Roselli M., Neciosup S., Burny W., Callegaro A., de Sousa Alves P. M., Louahed J., Brichard V. & Lehmann F. F. (20161213). A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. : Breast cancer research and treatment.

Chicago

Curigliano Giuseppe, Romieu Gilles, Campone Mario, Dorval Thierry, Duck Lionel, Canon Jean-Luc, Roemer-Becuwe Celia, Roselli Mario, Neciosup Silvia, Burny Wivine, Callegaro Andrea, de Sousa Alves Pedro Miguel, Louahed Jamila, Brichard Vincent and Lehmann Frédéric F. 20161213. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. : Breast cancer research and treatment.

Harvard

Curigliano G., Romieu G., Campone M., Dorval T., Duck L., Canon J., Roemer-Becuwe C., Roselli M., Neciosup S., Burny W., Callegaro A., de Sousa Alves P. M., Louahed J., Brichard V. and Lehmann F. F. (20161213). A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. : Breast cancer research and treatment.

MLA

Curigliano Giuseppe, Romieu Gilles, Campone Mario, Dorval Thierry, Duck Lionel, Canon Jean-Luc, Roemer-Becuwe Celia, Roselli Mario, Neciosup Silvia, Burny Wivine, Callegaro Andrea, de Sousa Alves Pedro Miguel, Louahed Jamila, Brichard Vincent and Lehmann Frédéric F. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. : Breast cancer research and treatment. 20161213.